Whitehawk Therapeutics raises $87.5M in PIPE, extends cash runway into H2 2028

Whitehawk Therapeutics, Inc.

Sells 4.33M shares at $3.92/share and 17.99M pre-funded warrants at $3.9199/warrant.
PIPE includes existing investors Avoro Capital, QVT, Coastlands, KVP, ADAR1, Acuta, StemPoint, Invus, and executives.
Expected close May 14, 2026; net proceeds for working capital and ADC pipeline advancement.
Cash runway extended into second half of 2028.
Lock-up agreements for executives/directors: 60 days post-closing.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Whitehawk Therapeutics, Inc. entered into Securities Purchase Agreement with each of the purchasers named therein (the "PIPE Investors") valued at $87,500,000 (effective 2026-05-12).

Action: entry
Agreement: equity purchase
Counterparty: each of the purchasers named therein (the "PIPE Investors")
Value: $87,500,000
Effective: 2026-05-12

Exact text from the filing

On May 12, 2026, Whitehawk Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with each of the purchasers named therein (the “PIPE Investors”), pursuant to which the Company agreed to sell to the PIPE Investors (i) 4,330,866 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), at a purchase price of $3.92 per share, and (ii) 17,991,021 pre-funded warrants to acquire Common Stock (the “Pre-Funded Warrants”), at a purchase price of $3.9199 per Pre-Funded Warrant, for an aggregate purchase price of $87,500,000 (collectively, the “PIPE Financing”).

View on SEC.gov

152 material agreements filed in the last 30 days. Browse all material agreements →

Whitehawk Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-220656

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.